RBX 7455
Alternative Names: Microbiota Restoration Therapy - Rebiotix; RBX-7455Latest Information Update: 28 Oct 2023
At a glance
- Originator Rebiotix
- Developer Mayo Clinic; Rebiotix
- Class Antibacterials; Antineoplastics; Bacteria
- Mechanism of Action Bacteria replacements; Gastrointestinal microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Clostridium difficile infections
- Phase II Hepatic encephalopathy
- No development reported Breast cancer
Most Recent Events
- 28 Oct 2023 No recent reports of development identified for phase-I development in Breast-cancer in USA (PO, Capsule)
- 13 Oct 2023 Rebiotix terminates a phase II trial for Hepatic Encephalopathy in the US (PO, Capsules), since the company was unable to recruit participants (NCT04155099)
- 04 Oct 2023 Mayo Clinic terminates phase I trial in Breast cancer in the US due to poor accrual (NCT04139993)